BD Licenses Technology to Advance Testing for Preeclampsia, Gestational Diabetes

BD has entered into a licensing and distribution agreement for clinical tests from DiabetOmics.

The company has developed new pregnancy-specific metabolic tests to provide early identification for preeclampsia and gestational diabetes. DiabetOmics has identified glycosylated fibronectin as a biological marker for the early identification of both conditions.

BD plans to create simple, affordable assays using GlyFn on its BD Veritor point-of-care diagnostic platform. BD also plans to distribute DiabetOmics’ own point-of-care tests and reader — currently in development — in select international markets. — Jonathon Shacat